Table 2.

Total agreements and Kappa coefficient among In-house ELISA and two commercially available serological assays.

Type of anti-SARS-COV-2 assays compared	Kappa	(95% CI)		Total agreements (%)	(95% CI)
		Lower	Upper		Lower	Upper
In-house ELISA vs Elecsys CLIA	0.61	0.55	0.67	80.79	75	86.6
In-house ELISA vs. Rapid LFA test (IgG + IgM)	0.52	0.46	0.58	75.79	70.1	81.5
In-house ELISA vs. Rapid LFA test IgM only	0.33	0.28	0.39	68.25	62.6	73.9
In-house ELISA vs. Rapid LFA test IgG only	0.58	0.52	0.63	78.95	73.2	84.7
Rapid LFA test (IgG + IgM) vs Elecsys	0.73	0.67	0.78	86.24	80.5	92
Elecsys CLIA vs. Rapid LFAtest IgM only	0.41	0.35	0.46	71.08	65.5	76.7
Elecsys CLIA vs Rapid LFA test (IgG only)	0.79	0.73	0.85	89.4	83.2	94.8